{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T16:30:05Z","timestamp":1787157005358,"version":"build-2736575974"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100022719","name":"The Darwin Trust of Edinburgh","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022719","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.metabol.2026.156711","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T06:43:06Z","timestamp":1785393786000},"page":"156711","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Complementary body weight and cardiometabolic benefits of higher GLP-1 and lower GIP: genetic evidence from large-scale phenomic analyses"],"prefix":"10.1016","volume":"183","author":[{"given":"Lijuan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangyuan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiqing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peige","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengfeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianzeng","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyan","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna C.","family":"Larsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos S.","family":"Mantzoros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2026.156711_bb0005","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"key":"10.1016\/j.metabol.2026.156711_bb0010","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s42255-020-00327-x","article-title":"Metabolic messengers: glucagon-like peptide 1","volume":"3","author":"Gribble","year":"2021","journal-title":"Nat Metab"},{"key":"10.1016\/j.metabol.2026.156711_bb0015","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s40265-022-01746-8","article-title":"Tirzepatide: first approval","volume":"82","author":"Syed","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.metabol.2026.156711_bb0020","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/s12933-021-01412-5","article-title":"The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect","volume":"20","author":"Fisman","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.metabol.2026.156711_bb0025","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2026.156711_bb0030","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2026.156711_bb0035","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Frias","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2026.156711_bb0040","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","article-title":"Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial","volume":"398","author":"Del Prato","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2026.156711_bb0045","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.2337\/db25-0393","article-title":"Therapeutic targeting of the GIP receptor-revisiting the controversies","volume":"74","author":"Campbell","year":"2025","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2026.156711_bb0050","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1210\/endo.133.1.8319572","article-title":"Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop","volume":"133","author":"Roberge","year":"1993","journal-title":"Endocrinology"},{"key":"10.1016\/j.metabol.2026.156711_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101139","article-title":"Targeting the GIPR for obesity: to agonize or antagonize? Potential mechanisms","volume":"46","author":"Campbell","year":"2021","journal-title":"Mol Metab"},{"key":"10.1016\/j.metabol.2026.156711_bb0060","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.2337\/dbi24-0027","article-title":"GIP receptor antagonists in the pharmacotherapy of obesity: physiologic, genetic, and clinical rationale","volume":"74","author":"Rosenkilde","year":"2025","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2026.156711_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.ahj.2013.07.012","article-title":"Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial","volume":"166","author":"Marso","year":"2013","journal-title":"Am Heart J"},{"key":"10.1016\/j.metabol.2026.156711_bb0070","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2026.156711_bb0075","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","article-title":"Semaglutide 2.4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2026.156711_bb0080","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.93306","article-title":"Genetic determinants of circulating GIP and GLP-1 concentrations","volume":"2","author":"Almgren","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.metabol.2026.156711_bb0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002937","article-title":"Genetically determined serum urate levels and cardiovascular and other diseases in UK Biobank cohort: a phenome-wide Mendelian randomization study","volume":"16","author":"Li","year":"2019","journal-title":"PLoS Med"},{"key":"10.1016\/j.metabol.2026.156711_bb0090","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1038\/ncomms5022","article-title":"Temporal disease trajectories condensed from population-wide registry data covering 6.2 million patients","volume":"5","author":"Jensen","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.metabol.2026.156711_bb0095","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1001\/jamacardio.2022.2333","article-title":"Joint genetic inhibition of PCSK9 and CETP and the association with coronary artery disease: a factorial Mendelian randomization study","volume":"7","author":"Cupido","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.metabol.2026.156711_bb0100","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1093\/ije\/dyz161","article-title":"Factorial Mendelian randomization: using genetic variants to assess interactions","volume":"49","author":"Rees","year":"2020","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.metabol.2026.156711_bb0105","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1038\/ng.3926","article-title":"Bayesian analysis of genetic association across tree-structured routine healthcare data in the UK Biobank","volume":"49","author":"Cortes","year":"2017","journal-title":"Nat Genet"},{"key":"10.1016\/j.metabol.2026.156711_bb0110","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/hmg\/ddy327","article-title":"Meta-analysis of genome-wide association studies for body fat distribution in 694 649 individuals of European ancestry","volume":"28","author":"Pulit","year":"2019","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.metabol.2026.156711_bb0115","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41586-018-0579-z","article-title":"The UK Biobank resource with deep phenotyping and genomic data","volume":"562","author":"Bycroft","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.metabol.2026.156711_bb0120","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1093\/ajcn\/nqac148","article-title":"Medical conditions associated with coffee consumption: disease-trajectory and comorbidity network analyses of a prospective cohort study in UK Biobank","volume":"116","author":"Hou","year":"2022","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.metabol.2026.156711_bb0125","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1038\/s41467-024-45445-2","article-title":"Disease clusters subsequent to anxiety and stress-related disorders and their genetic determinants","volume":"15","author":"Han","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.metabol.2026.156711_bb0130","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1016\/j.jacc.2018.09.051","article-title":"Impact of statins on cardiovascular outcomes following coronary artery calcium scoring","volume":"72","author":"Mitchell","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.metabol.2026.156711_bb0135","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.46928","article-title":"Restricted mean survival time analysis to estimate SGLT2i-associated heterogeneous treatment effects on primary and secondary prevention of cardiorenal outcomes in patients with type 2 diabetes in Taiwan","volume":"5","author":"Peng","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.metabol.2026.156711_bb0140","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2018.05.009","article-title":"Normal on-treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B","volume":"69","author":"Wong","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2026.156711_bb0145","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1056\/NEJMoa2210639","article-title":"Renin-angiotensin system inhibition in advanced chronic kidney disease","volume":"387","author":"Bhandari","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2026.156711_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2020.08.047","article-title":"Socioeconomic factors associated with liver-related mortality from 1985 to 2015 in 36 developed countries","volume":"19","author":"Li","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"Suppl. 1","key":"10.1016\/j.metabol.2026.156711_bb0155","doi-asserted-by":"crossref","first-page":"i46","DOI":"10.1093\/ije\/dyn031","article-title":"Design and implementation of a high-throughput biological sample processing facility using modern manufacturing principles","volume":"37","author":"Downey","year":"2008","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.metabol.2026.156711_bb0160","doi-asserted-by":"crossref","first-page":"425","DOI":"10.21037\/atm.2016.11.11","article-title":"Causal mediation analysis in the context of clinical research","volume":"4","author":"Zhang","year":"2016","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.metabol.2026.156711_bb0165","first-page":"1013","volume":"68","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.metabol.2026.156711_bb0170","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1001\/jama.2018.14854","article-title":"The physical activity guidelines for Americans","volume":"320","author":"Piercy","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.metabol.2026.156711_bb0175","first-page":"245","article-title":"American Cancer Society guideline for diet and physical activity for cancer prevention","volume":"70","author":"Rock","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.metabol.2026.156711_bb0180","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1007\/s00125-016-4090-5","article-title":"Investigation of gene-diet interactions in the incretin system and risk of type 2 diabetes: the EPIC-InterAct study","volume":"59","author":"InterAct C","year":"2016","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2026.156711_bb0185","doi-asserted-by":"crossref","first-page":"6109","DOI":"10.1038\/s41467-022-33867-9","article-title":"The metabolic effects of adding exenatide to basal insulin therapy when targeting remission in early type 2 diabetes in a randomized clinical trial","volume":"13","author":"Retnakaran","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.metabol.2026.156711_bb0190","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.2337\/dc19-0883","article-title":"Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial","volume":"42","author":"Rodbard","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2026.156711_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol Metab"},{"key":"10.1016\/j.metabol.2026.156711_bb0200","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2026.156711_bb0205","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cmet.2016.06.009","article-title":"The cardiovascular biology of glucagon-like peptide-1","volume":"24","author":"Drucker","year":"2016","journal-title":"Cell Metab"},{"key":"10.1016\/j.metabol.2026.156711_bb0210","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21041509","article-title":"GIP as a potential therapeutic target for atherosclerotic cardiovascular disease-a systematic review","volume":"21","author":"Mori","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.metabol.2026.156711_bb0215","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.cmet.2017.11.003","article-title":"Inactivation of the glucose-dependent insulinotropic polypeptide receptor improves outcomes following experimental myocardial infarction","volume":"27","author":"Ussher","year":"2018","journal-title":"Cell Metab"},{"key":"10.1016\/j.metabol.2026.156711_bb0220","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2337\/db15-0122","article-title":"Glucose-dependent insulinotropic polypeptide stimulates osteopontin expression in the vasculature via endothelin-1 and CREB","volume":"65","author":"Berglund","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2026.156711_bb0225","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s00125-020-05093-9","article-title":"Glucose-dependent insulinotropic peptide and risk of cardiovascular events and mortality: a prospective study","volume":"63","author":"Jujic","year":"2020","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2026.156711_bb0230","doi-asserted-by":"crossref","first-page":"224","DOI":"10.2337\/dc20-1318","article-title":"Glucose-dependent insulinotropic peptide in the high-normal range is associated with increased carotid intima-media thickness","volume":"44","author":"Jujic","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2026.156711_bb0235","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007218","article-title":"Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans","volume":"5","author":"Finan","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.metabol.2026.156711_bb0240","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.cmet.2017.07.011","article-title":"The sustained effects of a dual GIP\/GLP-1 receptor agonist, NNC0090-2746, in patients with type 2 diabetes","volume":"26","author":"Frias","year":"2017","journal-title":"Cell Metab"},{"key":"10.1016\/j.metabol.2026.156711_bb0245","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41574-022-00783-3","article-title":"Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1","volume":"19","author":"Hammoud","year":"2023","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.metabol.2026.156711_bb0250","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat3392","article-title":"Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models","volume":"10","author":"Killion","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.metabol.2026.156711_bb0255","doi-asserted-by":"crossref","first-page":"3786","DOI":"10.1172\/JCI126107","article-title":"Gut-derived GIP activates central Rap1 to impair neural leptin sensitivity during overnutrition","volume":"129","author":"Kaneko","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.metabol.2026.156711_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2022.101638","article-title":"Discovery of a potent GIPR peptide antagonist that is effective in rodent and human systems","volume":"66","author":"Yang","year":"2022","journal-title":"Mol Metab"},{"key":"10.1016\/j.metabol.2026.156711_bb0265","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1111\/dom.14736","article-title":"Acute concomitant glucose-dependent insulinotropic polypeptide receptor antagonism during glucagon-like peptide 1 receptor agonism does not affect appetite, resting energy expenditure or food intake in patients with type 2 diabetes and overweight\/obesity","volume":"24","author":"Stensen","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2026.156711_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106058","article-title":"GIP and GLP-2 together improve bone turnover in humans supporting GIPR-GLP-2R co-agonists as future osteoporosis treatment","volume":"176","author":"Gabe","year":"2022","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.metabol.2026.156711_bb0275","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2019.00075","article-title":"Gut hormones and their effect on bone metabolism. Potential drug therapies in future osteoporosis treatment","volume":"10","author":"Schiellerup","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.metabol.2026.156711_bb0280","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.153732","article-title":"Differential importance of endothelial and hematopoietic cell GLP-1Rs for cardiometabolic versus hepatic actions of semaglutide","volume":"6","author":"McLean","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.metabol.2026.156711_bb0285","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1089\/dia.2024.0496","article-title":"Enhancing type 1 diabetes immunological risk prediction with continuous glucose monitoring and genetic profiling","volume":"27","author":"Montaser","year":"2025","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.metabol.2026.156711_bb0290","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1177\/19322968251333441","article-title":"The use of continuous glucose monitoring to diagnose stage 2 type 1 diabetes","volume":"19","author":"Mader","year":"2025","journal-title":"J Diabetes Sci Technol"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049526002246?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049526002246?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T16:00:34Z","timestamp":1787155234000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049526002246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":58,"alternative-id":["S0026049526002246"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2026.156711","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Complementary body weight and cardiometabolic benefits of higher GLP-1 and lower GIP: genetic evidence from large-scale phenomic analyses","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2026.156711","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"156711"}}